November 30, 2018

Turnstone Biologics Unveils Novel Vaccinia Oncolytic Viral Immunotherapy Platform

NEW YORK & OTTAWA, Ontario–(BUSINESS WIRE)–Turnstone Biologics, a clinical-stage immuno-oncology company leading the next generation of oncolytic viral therapies, presented pre-clinical data today supporting the development of a new Vaccinia therapeutic platform at the American Association for Cancer Research Tumor Immunology and Immunotherapy Meeting in Miami. This platform was developed by Dr. John Bell and his colleagues at The Ottawa Hospital Research Institute and the University of Ottawa, and engineered to be potent, highly selective and immune-stimulatory. Furthermore, the versatility of the platform enables additional therapeutic agents to be encoded in the virus and produced at tumor sites. This single platform virus has the potential to create a portfolio of diverse products. Turnstone has exclusively licensed this technology.

This proprietary Vaccinia virus can be delivered systemically and is designed to target and kill cancer cells throughout the body, modulate the tumor microenvironment and stimulate both innate and adaptive immune responses. The virus also contains a very large transgene capacity, allowing for the insertion of multiple therapeutic agents. These agents will be produced selectively at tumor sites as the virus replicates only in the tumor cells, effectively enabling a local combination therapy from a single therapeutic promoting cancer cell killing. Turnstone is conducting IND-enabling studies on TBio-6517, its lead product candidate from this platform, consisting of the Vaccinia virus expressing three potent immune modulators, and anticipates initiating clinical studies in 2019.

Read more

Back to News